Following this activity, participants should be able to: Describe how to select appropriate testing methods to optimize biomarker detection and target therapy selection. Recognize when it is necessary to look for information beyond the prescribing information to determine clinical actionability. Demonstrate how to find information on the actionability of genetic variants by using a precision oncology database.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96352
- Start Date: 2025-02-28 06:00:00
- End Date: 2025-02-28 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 20000.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 25000.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest